丸美生物：向香港联交所递交H股发行上市申请

Core Points - Company Marubi Biotechnology (603983) submitted an application for H-share issuance and listing to the Hong Kong Stock Exchange on December 11, 2025, with the application materials published on the exchange's website on the same day [1] Issuance Arrangement - The issuance is limited to specific investor groups, including Hong Kong public investors, qualified overseas investors, and domestic qualified investors eligible for overseas securities investment [2] - The listing will take place on the main board of the Hong Kong Stock Exchange [2] - The application materials are in draft form and may be updated or revised, pending approval from regulatory bodies such as the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange [2] - The company has provided links to the application materials in both Chinese and English on the Hong Kong Stock Exchange website for domestic investors to access relevant information [2]